Lue et al. found that combined Src-STAT3 inhibition using dasatinib and CYT387 (a JAK/STAT inhibitor) synergistically reduced cell proliferation and increased apoptosis in RCC cells [75]. This evidence concerns the gene SOAT1 and renal cell carcinoma.